SEOUL, South Korea, Dec. 15, 2025 — Lunit (KRX: 328130), a provider of AI for cancer diagnostics and precision oncology, has entered a collaboration with Daiichi Sankyo (TSE: 4568) to integrate Lunit SCOPE digital pathology products in two oncology research and development programs.
Daiichi Sankyo will deploy Lunit SCOPE IO for immune phenotyping and spatial analysis and SCOPE universal IHC (uIHC) for quantitative immunohistochemistry to support biomarker discovery, translational research and patient stratification. The companies said the collaboration aims to accelerate identification of novel biomarkers, potentially inform clinical trial enrichment strategies and refine development plans across multiple cancer types.
“Lunit SCOPE was built to unlock hidden insights from pathology slides — quantifying the tumor microenvironment, predicting molecular profiles and generating data-rich features to inform trial design,” said Brandon Suh, CEO of Lunit. “By working with Daiichi Sankyo, we are embedding these capabilities into translational and clinical research to enable faster biomarker discovery and more precise patient stratification.”
The work will include exploratory projects and analyses across two oncology assets and multiple tumor types, with the potential to shape future trial designs, biomarker strategies and clinical development pathways.
About Lunit
Founded in 2013, Lunit develops AI-driven solutions for cancer detection and precision oncology. Its products range from screening and risk-prediction tools to biomarker analysis platforms used in research partnerships and companion diagnostic development. Lunit’s FDA-cleared imaging solutions and the Lunit SCOPE platform are used by thousands of institutions worldwide. The company is headquartered in Seoul and operates globally; more information is available at lunit.io/en.
Leave a Reply